Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole 40 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

NCT03083639
View directory record Official record
Conditions
Healthy Participants
Interventions
Esomeprazole Capsule, Esomeprazole Tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 2 Interventional Results available

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT00474903
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
acetylsalicylic acid, esomeprazole magnesium, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

NCT00206050
View directory record Official record
Conditions
Healthy
Interventions
Esomeprazole, pantoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 21, 2011 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

NCT05468164
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 5, 2026, 3:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

NCT01129713
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions
Secretol, Nexium
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3484356 in Healthy Female Participants

NCT04840888
View directory record Official record
Conditions
Healthy
Interventions
LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC Aspirin 325
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Omeprazole and PA21

NCT01452906
View directory record Official record
Conditions
Healthy
Interventions
PA21 and Omeprazole with food, No PA21; Omeprazole with food, PA21 with food, Omeprazole 2hrs later
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

NCT00446004
View directory record Official record
Conditions
Healthy
Interventions
Imatinib Mesylate, Omeprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Calcium carbonate, Omeprazole, Rifampin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

NCT03137134
View directory record Official record
Conditions
Healthy
Interventions
Crizotinib, Esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Prilosec Bioequivalence Study in Healthy Volunteers

NCT01921920
View directory record Official record
Conditions
Bioequivalence, AUC, Cmax, Pharmacokinetics
Interventions
Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

NCT03866434
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SPD422, Omeprazole
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Dexlansoprazole on Bone Homeostasis

NCT01216293
View directory record Official record
Conditions
Homeostasis, Bone and Bones
Interventions
Dexlansoprazole, Esomeprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
Up to 75 Years · Female only
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 4 Interventional Results available

Ulcer Prevention Study in Post Gastric Bypass Patients

NCT00557349
View directory record Official record
Conditions
Marginal Ulcers
Interventions
Omeprazole, Famotidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

NCT02023125
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
TERN-701, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment and Management of Chronic Dyspepsia in Eastern Uganda

NCT04525664
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
Clarithromycin 500mg, Amoxicillin 1000 MG, Omeprazole 40 MG, Omeprazole 20 MG Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 5, 2026, 3:31 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 5, 2026, 3:31 PM EDT